CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionReturn on equity is -333%, lower than 95% of its Biotechnology peers (median -24.5%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.32BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
3.14xvs all stocks
52-Week Change
11.80%vs all stocks
Market Capitalization
2.32BUSDvs all stocks (USD)
Enterprise Value
2.18BUSDvs all stocks (USD)
Forward P/E
-7.27xvs Biotechnology peers
Price to Book (MRQ)
16.48xvs Biotechnology peers
Enterprise to EBITDA
-3.58xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-83.38%vs Biotechnology peers
Return on Equity (TTM)
-333.00%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 18, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-607.19MUSDvs all stocks (USD)
Net Income (TTM)
-647.68MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-594.23MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-379.37MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-745.38MUSDvs all stocks (USD)
Pre-tax Income
-737.38MUSDFY2025 · Dec 31, 2025Income Tax Expense
1.44MUSDFY2025 · Dec 31, 2025Net Income
-738.82MUSDFY2025 · Dec 31, 2025EBIT
-745.38MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-735.46MUSDFY2025 · Dec 31, 2025Research & Development
635.07MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
110.31MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-738.82MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-617.91MUSDFY2025 · Dec 31, 2025Free Cash Flow
-618.62MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
232.78MUSDFY2025 · Dec 31, 2025Income Tax Paid
133.00KUSDFY2025 · Dec 31, 2025Interest Paid
216.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-738.82MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
9.92MUSDFY2025 · Dec 31, 2025Stock-based Compensation
112.36MUSDFY2025 · Dec 31, 2025Other Non-cash Items
5.02MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-6.39MUSDFY2025 · Dec 31, 2025Capital Expenditures
-715.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-266.88MUSDFY2025 · Dec 31, 2025Sale of Investments
570.00MUSDFY2025 · Dec 31, 2025Other Investing Activity
-1.85MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
300.56MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
250.00MUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.89MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
437.28MUSDFY2025 · Dec 31, 2025Shares Outstanding
150.51MSharesUpdated Jul 18, 2026Float Shares
124.00MSharesUpdated Jul 18, 2026Shares Short
20.47MSharesUpdated Jul 18, 2026Short Ratio
5.15daysvs all stocks
Short % of Shares Outstanding
17.41%vs all stocks
% Held by Insiders
11.08%vs all stocks
% Held by Institutions
91.60%vs all stocks
Total Cash (MRQ)
347.82MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.31USDUpdated Jul 18, 2026Total Debt (MRQ)
286.18MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
2.21xvs Biotechnology peers
Current Ratio (MRQ)
7.41xvs Biotechnology peers
Book Value per Share (MRQ)
0.8600USDUpdated Jul 18, 2026Total Assets
451.45MUSDvs all stocks (USD)
Total Current Assets
368.33MUSDFY2025 · Dec 31, 2025Total Liabilities
399.38MUSDFY2025 · Dec 31, 2025Total Non-current Assets
83.12MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
283.44MUSDFY2025 · Dec 31, 2025Total Current Liabilities
115.93MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
229.96MUSDFY2025 · Dec 31, 2025Other Short-term Investments
89.18MUSDFY2025 · Dec 31, 2025Accounts Payable
11.64MUSDFY2025 · Dec 31, 2025Short-term Debt
5.76MUSDFY2025 · Dec 31, 2025Other Current Liabilities
42.71MUSDFY2025 · Dec 31, 2025Long-term Debt
278.86MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
4.58MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.93BUSDFY2025 · Dec 31, 2025Retained Earnings
-2.08BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
52.07MUSDvs all stocks (USD)
52-Week Low
7.48USDUpdated Jul 18, 202652-Week High
18.57USDUpdated Jul 18, 202652-Week Change
11.80%vs all stocks
Beta
3.14xvs all stocks
50-Day MA
12.15USDUpdated Jul 18, 2026200-Day MA
11.65USDUpdated Jul 18, 2026Avg 10-Day Volume
2.11MSharesUpdated Jul 18, 2026Avg 30-Day Volume
3.48MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-5.57USDUpdated Jul 18, 2026Other Income / Expense
8.00MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -333%, lower than 95% of its Biotechnology peers (median -24.5%)Significant
Return on equity: -3.33Industry median: -0.25Industry P5: -1.55Peers compared: 197
Return on assets is -83.4%, lower than 95% of its Biotechnology peers (median -21.3%)Significant
Return on assets: -0.83Industry median: -0.21Industry P5: -0.74Peers compared: 197
Structural Tensions
Significant cash reserves alongside high leverageNotable
Cash (USD): 347,816,992Total Debt (USD): 286,175,008Debt-to-Equity: 2.21
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.51
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Levered free cash flow is -$379.37M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -379,373,312Global P5: -219,013,500
Market cap is $2.32B, above the global median of $1.15BNotable
Market cap (USD): 2,324,661,685Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nektar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Agios Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
BioCryst Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangzhong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Prestige Consumer Healthcare Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Voronoi, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Pell Bio-Med Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
BrightGene Bio-Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule